In addition, Steven E Kahn outlines the clinical learnings from the SELECT trial, revealing positive effects of GLP-1 receptor agonists in people with cardiovascular disease who do not have diabetes, as published in the New England Journal of Medicine in November 2023. Last but not least, Julia Mader focuses on type 1 diabetes and technological updates in her key takeaways from the second conference day. She also gives an outlook on what’s coming on EASD e-Learning over the summer: our Features series. Get all the ins and outs in the video below.